You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Indication 1

Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

Dosage 1

Bexsero is available as a white opalescent liquid suspension for injection in a pre-filled syringe and comes as a 0.5 ml dose.

Bexsero offers several schedule options with flexible dosing intervals, making it simple to fit with routine vaccination visits. 1

Bexsero Overview

The use of this vaccine should be in line with official recommendations.


Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines 1:

— Meningococcal groups A, C, W, Y conjugate

— Diphtheria, tetanus, acellular pertussis, inactivated polio

Haemophilus influenzae type b

— Hepatitis B

— Heptavalent pneumococcal conjugate

— Measles, mumps, rubella

— Varicella

Storage and stability 1

  • Shelf life: 3 years
  • Store in a refrigerator (2°C–8°C)
  • Do not freeze
  • Store in the original package in order to protect from light
  • Upon storage, a fine off-white deposit may be observed in the prefilled syringe containing the suspension
  • Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension. 

View Resources


  1. Bexsero Summary of Product Characteristics. Available at: Last Accessed: April 2021
  2. HSE Immunisation Guidelines. Available at:, Last Accessed: April 2021

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Bexsero is a registered trademark of the GlaxoSmithKline Group of Companies